Johnson & Johnson procures Ambrx Biopharma to Develop Oncology Portfolio

Johnson & Johnson has acquired Ambrx Biopharma for $2 billion to develop their oncology platform with a focus on prostate cancer.  

Ambrx Biopharma is a biotechnology company that focuses on the development of protein therapeutics such as antibody-drug conjugates.  

Incorporating Ambrx’s ADC portfolio into Johnson & Johnson’s lineup offers a distinctive chance to progress the creation and marketing of precision oncology treatments.  

Johnson & Johnson will obtain entry to the Ambrx portfolio, which includes potential treatments for various cancer indications.  

Yusri Elsayed, the head of oncology medicine at Johnson & Johnson, stated, “We’re pleased to welcome Ambrx’s talented scientific team and ADC platform to Johnson & Johnson.”  

Elsated went on to add, “This significant opportunity sets the stage for advancing next-generation ADCs to deliver differentiated solid tumour therapies that improve patients’ lives.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.